Emergent BioSolutions (EBS) Misses Q2 EPS by $1.21
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.50 -1.96%
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.33, $1.21 worse than the analyst estimate of $1.54. Revenue for the quarter came in at $397.5 million versus the consensus estimate of $398.93 million.
GUIDANCE:
Emergent BioSolutions sees Q3 2021 revenue of $1700-1900 billion, versus the consensus of $1.8 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- XP Inc eyes US banking license as next business step
- L3Harris CEO steps down amid conduct review, shares drop
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
